VIVE News and Press, Viveve Medical Inc. From 10/04/22

Patent issuance further strengthens Viveve's intellectual property portfolio for the treatment of female stress urinary incontinence ENGLEWOOD, CO / ACCESSWIRE / October 4, 2022 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's health and the treatmen...

New branding reflects Company's vision to be the leader in the treatment of Stress Urinary Incontinence in Women Completion of PURSUIT follow-up visits anticipated by the end of 2022 with topline results expected shortly thereafter ENGLEWOOD, CO / ACCESSWIRE / September 27, 2022 / ...

ENGLEWOOD, CO / ACCESSWIRE / September 22, 2022 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's health and the treatment of stress urinary incontinence (SUI), today announced that Scott Durbin, chief executive officer, will participate in the Ladenburg T...

ENGLEWOOD, CO / ACCESSWIRE / September 15, 2022 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's health and the treatment of stress urinary incontinence (SUI), today announced that Scott Durbin, chief executive officer, will participate in the Alliance ...

ENGLEWOOD, CO / ACCESSWIRE / September 1, 2022 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's health and the treatment of stress urinary incontinence (SUI), today announced that Scott Durbin, chief executive officer, will participate in the H.C. Wainwri...

Viveve Medical, Inc. (VIVE) Q2 2022 Earnings Conference Call August 11, 2022, 05:00 PM ET Company Participants Jeannie Swindle - Senior Director, Corporate Communications Jim Robbins - SVP, Finance and Administration Scott Durbin - CEO Conference Call Parti...

Viveve Medical press release ( NASDAQ: VIVE ): Q2 GAAP EPS of -$0.67 in-line. Revenue of $1.8M (+9.1% Y/Y) beats by $0.04M . For further details see: Viveve Medical GAAP EPS of -$0.67 in-line, revenue of $1.8M beats by $0.04M

Total revenue of $1.8 million in Q2 including sale of 2,850 disposable treatment tips PURSUIT clinical trial follow-up visit completion anticipated by year end Conference call to be hosted by Company at 5:00 PM ET today ENGLEWOOD, CO / ACCESSWIRE / August 11, 2022 / Viveve Med...

ENGLEWOOD, CO / ACCESSWIRE / July 28, 2022 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's health and the treatment of stress urinary incontinence (SUI), today announced that it will report its second quarter 2022 financial results and provide a corporat...

Medical technology company Viveve Medical ( NASDAQ: VIVE ) received a patent for the company's dual-energy technology by the Taiwan Intellectual Property Office. The Taiwan Patent No. I766557 further expands and strengthens VIVE's intellectual property portfolio in the&#x...